Hatteras’ latest wave of cash arrives in two funds: Finance Report

Hatteras Venture Partners is the latest life sciences investment firm to raise a later-stage fund alongside its core early-stage vehicle, drawing more than $200 million to back biotech, medtech and health technology companies.

The Durham, N.C.-based firm said Wednesday it had raised its largest core fund yet, the $177 million Fund VII, with an eye toward seed and early-stage investments. General Partner Clay Thorp told BioCentury that the firm’s other new fund, Hatteras Opportunity Fund I, will have about $30 million to invest “in any Hatteras portfolio company; it just has to invest in a subsequent round.”...